Royalty Pharma Third Quarter 2024 Earnings: EPS: US$0.92 (vs US$0.16 in 3Q 2023)

Royalty Pharma (NASDAQ:RPRX) Third Quarter 2024 Results

Key Financial Results

• Revenue: US$565.0m (up 5.3% from 3Q 2023).
• Net income: US$544.0m (up by US$471.9m from 3Q 2023).
• Profit margin: 96% (up from 13% in 3Q 2023). The increase in margin was primarily driven by lower expenses.
• EPS: US$0.92 (up from US$0.16 in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Royalty Pharma Earnings Insights

Looking ahead, revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are down 1.8% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Royalty Pharma, and understanding them should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.